Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3201
CALL
Ferguson
FERG
$43.2B
| $1.34M | ﹤0.01% |
+6,000
| New | +$1.43M |
2025 Q4
0 quarters
|
|
3202
Microvast
MVST
$248M
| $1.33M | ﹤0.01% |
475,068
+87,247
| +22% | +$365K |
2022 Q1
15 quarters
|
|
3203
Limbach Holdings
LMB
$586M
| $1.33M | ﹤0.01% |
17,068
+1,263
| +8% | +$104K |
2023 Q1
11 quarters
|
|
3204
CALL
ProPetro Holding
PUMP
$1.14B
| $1.33M | ﹤0.01% |
+139,700
| New | +$1.21M |
2025 Q4
0 quarters
|
|
|
NUTX
3205
Nutex Health
NUTX
$1.48B
| $1.33M | ﹤0.01% |
8,063
+3,155
| +64% | +$418K |
2025 Q2
2 quarters
|
|
3206
Lincoln Educational Services
LINC
$695M
| $1.32M | ﹤0.01% |
54,852
+11,818
| +27% | +$258K |
2023 Q2
10 quarters
|
|
3207
Ironwood Pharmaceuticals
IRWD
$601M
| $1.32M | ﹤0.01% |
392,904
+95,586
| +32% | +$248K |
2013 Q2
50 quarters
|
|
|
INVX
3208
Innovex International
INVX
$1.91B
| $1.32M | ﹤0.01% |
60,458
+5,640
| +10% | +$118K |
2013 Q2
50 quarters
|
|
3209
Monopar Therapeutics
MNPR
$523M
| $1.32M | ﹤0.01% |
20,245
+5,163
| +34% | +$422K |
2025 Q1
3 quarters
|
|
3210
Birkenstock
BIRK
$5.5B
| $1.32M | ﹤0.01% |
32,313
+31,677
| +4,981% | +$1.34M |
2023 Q4
8 quarters
|
|
3211
Caledonia Mining Corp
CMCL
$464M
| $1.32M | ﹤0.01% |
50,473
+13,178
| +35% | +$387K |
2020 Q2
22 quarters
|
|
3212
CALL
Biogen
BIIB
$32.5B
| $1.32M | ﹤0.01% |
7,500
| – | – |
2025 Q3
1 quarter
|
|
|
AGNT
3213
AGNT Inc
AGNT
$610M
| $1.32M | ﹤0.01% |
145,594
+11,909
| +9% | +$126K |
2019 Q1
27 quarters
|
|
|
ATXS
3214
DELISTED
Astria Therapeutics
ATXS
| $1.31M | ﹤0.01% |
100,427
-6,682
| -6% | -$79.8K |
2023 Q1
11 quarters
|
|
|
SAFE
3215
Safehold
SAFE
$854M
| $1.31M | ﹤0.01% |
95,682
+6,291
| +7% | +$89.4K |
2013 Q2
50 quarters
|
|
3216
Energy Recovery
ERII
$346M
| $1.31M | ﹤0.01% |
97,060
+6,292
| +7% | +$95.4K |
2016 Q4
36 quarters
|
|
3217
Malibu Boats
MBUU
$453M
| $1.31M | ﹤0.01% |
46,413
+2,692
| +6% | +$78.1K |
2016 Q1
39 quarters
|
|
3218
Dream Finders Homes
DFH
$973M
| $1.3M | ﹤0.01% |
76,161
+14,554
| +24% | +$298K |
2023 Q4
8 quarters
|
|
3219
Idaho Strategic Resources
IDR
$437M
| $1.3M | ﹤0.01% |
32,313
+4,102
| +15% | +$157K |
2024 Q2
6 quarters
|
|
3220
Integra LifeSciences
IART
$986M
| $1.3M | ﹤0.01% |
104,564
+10,101
| +11% | +$134K |
2016 Q1
39 quarters
|
|
3221
American Public Education
APEI
$800M
| $1.3M | ﹤0.01% |
34,348
-554
| -2% | -$19.8K |
2013 Q2
50 quarters
|
|
3222
PUT
Zillow
Z
$6.16B
| $1.3M | ﹤0.01% |
19,000
| – | – |
2024 Q3
5 quarters
|
|
3223
First Watch Restaurant Group
FWRG
$652M
| $1.3M | ﹤0.01% |
85,916
-15,577
| -15% | -$263K |
2022 Q1
15 quarters
|
|
3224
Butterfly Network
BFLY
$2.38B
| $1.3M | ﹤0.01% |
340,825
+65,792
| +24% | +$179K |
2022 Q1
15 quarters
|
|
3225
Orthofix Medical
OFIX
$370M
| $1.29M | ﹤0.01% |
85,227
-50,250
| -37% | -$767K |
2013 Q4
48 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.